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Abstract: Arterial stiffness plays a key role in the pathophysiology of the cardiovascular system. 
Some indices of arterial stiffness (pulse wave velocity, augmentation index, characteristics of 
central blood pressure waveform) may be presently calculated and evaluated in the clinical 
setting. Age and blood pressure are the two major clinical determinants of increased arterial 
stiffness, while molecular determinants of arterial stiffness are related to fibrotic components 
of the extracellular matrix, mainly elastin, collagen and fibronectin. Increased arterial stiffness 
has been consistently observed in conditions such as hypertension, dyslipidemia and dia-
betes. Arterial stiffness evaluated by means of carotid-femoral pulse wave velocity yielded 
prognostic significance beyond and above traditional risk factors. A more favorable effect of 
calcium channel blockers, diuretics and ACE inhibitors compared with β-blockers on indices 
of arterial stiffness was observed in several studies. It is conceivable that newer β-blockers 
with additional vasodilating properties, such as nebivolol, which has favorable effects on 
carbohydrate and lipid metabolism, as well as on endothelial function and on oxidative stress, 
may have favorable effects on arterial stiffness, compared with atenolol. In fact, in recent studies, 
nebivolol was demonstrated to improve artery stiffness to a greater extent than older β-blockers. 
Because endothelial dysfunction and increased arterial stiffness play an important role in the 
early atherosclerotic processes and are associated with poor outcomes and increased mortality, 
independently of blood pressure, the ability of nebivolol to enhance release of endothelium-
derived nitric oxide, and consequently improve endothelial function and arterial stiffness, may 
have significant clinical implications for the use of this agent in the treatment of hypertension 
and cardiovascular diseases.
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Introduction
Arterial stiffness plays a key role in the pathophysiology of the cardiovascular sys-
tem. During systole, the left ventricle increases the pressure in large vessels, which, 
owing to their elastic properties, may store a significant part of the left ventricle ejec-
tion volume.1 After the closure of the aortic valve, the recoil of the large vessels to 
their diastolic dimensions pushes the blood towards the periphery. This mechanism 
allows to reconcile the intermittent contraction of the left ventricle with the perma-
nent need of tissues for oxygen and nutriments.1 This phenomenon is quantitatively 
larger in healthy and younger subjects.2 Arterial compliance favors left ventricular 
function as it reduces left ventricular workload, and enhances diastolic perfusion, 
crucial to the delivery of blood to the myocardium through the coronary vessels. As 
the propagation of the pressure wave in elastic tubes occurs at a definite velocity, it 
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is possible to measure arterial stiffness through the pulse 
wave velocity (PWV). Aortic stiffness is approximated by 
the carotid to femoral pulse wave velocity (typical value: 
8 m/s).1,3 In addition, the pressure wave can reflect from the 
peripheral vasculature (branching, resistance, stenosis), and 
return towards the heart.1 When stiffness is high, the returned 
wave may add to the ejection pressure. In physiological 
conditions, the reflected pressure wave returns in diastole, 
explaining why the systolic and pulse pressures measured 
close to the heart (central blood pressure) are lower than at 
the periphery (Figure 1).4
Age and blood pressure are the two major determinants 
of increased arterial stiffness.1,5 Molecular determinants of 
arterial stiffness are related to the fibrotic components of 
the extracellular matrix (ECM), mainly elastin, collagen 
and fibronectin. Increased arterial stiffness was consistently 
observed in conditions such as hypertension, dyslipidemia 
and diabetes.1 As blood vessels become stiffer because of age-
related processes, the pulse wave is transmitted more rapidly 
and returns to the heart during left ventricular contraction, 
resulting in a greater augmentation of the central aortic systolic 
pressure. It is therefore possible to quantify this effect through 
the calculation of the augmentation index (Figure 2).
Several studies have underlined the role of inflammation 
in the stiffening of large arteries. Various mechanisms may 
be involved, including endothelial dysfunction, release of 
inducible matrix metalloproteinases, medial calcifications, 
changes in proteoglycan composition and state of hydration, 
as well as cellular infiltration around the vasa vasorum 
leading to vessels ischemia.1 The association between arterial 
stiffening and inflammation in essential hypertension has 
been demonstrated through the relationships between arterial 
stiffness and either tumor necrosis factor-alpha (TNF-a), 
interleukin-6 (IL-6), or high sensitive C-reactive protein 
(hs-CRP).6,7 Baseline hs-CRP was not only an independent 
predictor of carotid-femoral pulse wave velocity and central 
augmentation index,6 but also of the reduction in peripheral 
pulse pressure after antihypertensive treatment during the 
REASON study.7
Arterial stiffness  
as a cardiovascular risk factor
Alterations in the mechanical properties of large arteries 
have a clear pathophysiological link with clinical outcome. 
In addition to being a measure of the cumulative influence 
of identified and unidentified cardiovascular risk factors on 
target organ damage, changes of large artery phenotype may 
be causative in the pathogenesis of cardiovascular events.1 
An expert consensus document on arterial stiffness has 





























Figure 1 Change in contours in pressure wave (top) and flow wave (bottom) between the ascending aorta and the saphenous artery. Reproduced with permission from 
Agabiti-Rosei e, Mancia G, O’Rourke MF, et al Central blood pressure measurements and antihypertensive therapy: a consensus document. Hypertension. 2007;50:154–160.4 
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11 longitudinal studies have been listed demonstrating that 
a simple measure of aortic stiffness through carotid-femoral 
PWV yielded prognostic values beyond and above traditional 
risk factors.3
In addition, increased aortic augmentation index is 
associated with coronary artery disease.4 Central pressures 
also correlate with cardiovascular risk not only in patients 
with atherosclerotic disease but also in apparently healthy 
subjects. The late systolic augmentation of the central pressure 
waveform is associated with an increase in left ventricular 
mass index independent of age and mean blood pressure4 and 
carotid systolic blood pressure is an independent determinant 
of left ventricular wall thickness. Moreover, central pressure 
is also more closely related than brachial pressure to other 
important cardiovascular intermediate end points, such as 
vascular hypertrophy, extent of carotid atherosclerosis, and 
ascending aorta diameter.4
Arterial stiffness  
and antihypertensive treatment
The effects of antihypertensive treatment with angiotensin 
converting enzyme (ACE) inhibitors on arterial stiffness and 
wave reflections were investigated by evaluation of brachial 
and carotid systolic blood pressure and pulse pressure 
(indirect indices of arterial stiffness) in the REASON Study 
(preterax in REgression of Arterial Stiffness in a contrOlled 
double-bliNd study)8 and further firmly confirmed.9,10 The 
REASON Study was a controlled trial that compared the 
β-blocking agent atenolol to a low dose combination of 
the diuretic indapamide with the ACE inhibitor perindopril. 
After 1 year, for the same diastolic blood pressure reduction, 
the combination of perindopril and indapamide induced a 
more pronounced reduction of brachial (peripheral artery) 
and carotid (central artery) systolic blood pressure or pulse 
pressure than atenolol.8 The more evident reduction of central 
pulse pressure induced by the combination perindopril-
indapamide was associated to a more pronounced reduction 
of cardiac mass.11 The two drug regimens induced the 
same aortic PWV reduction as a result of the comparable 
decreases of mean or diastolic arterial pressures.12 The 
major difference between the two therapeutic approaches 
was that perindopril/indapamide but not atenolol reduced 
carotid augmentation index, a reliable marker of carotid 
wave reflections.12 Several mechanisms may be involved 
in the observed differences between the two therapeutic 
approaches. The atenolol-induced heart rate decrease may 
have caused the maintenance of disturbed wave reflections,12 
since it has been previously demonstrated that a slow heart 
rate can also affect pulse wave velocity and augmentation of 
central aortic systolic pressure.13 However, a bradycardiac 
response was observed only within the first 6 months of 
treatment.8 It is possible that perindopril, but not atenolol, 
may have improved micro and macrovascular structure, by 
preventing structural alterations at different levels, and this 
aspect was previously addressed in details.12 In addition, ACE 
inhibitors, but not atenolol, are known to reduce reflection 
coefficients,14,16 thus reducing the reflection of waves from 








Figure 2 Central pressure waveform. The height of the late systolic peak above the inflection defines the augmented pressure, and the ratio of augmented pressure to pulse 
pressure identifies the augmentation index (in percent). Reproduced with permission from Agabiti-Rosei E, Mancia G, O’Rourke MF,  et al.  Central blood pressure measurements 
and antihypertensive therapy: a consensus document. Hypertension. 2007;50:154–160.4 Copyright © 2007 Lippincott williams & wilkins.Vascular Health and Risk Management 2009:5 356
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study (Conduit Artery Function Evaluation),10 the different 
effects of atenolol/hydrochlorothiazide and amlodipine/
perindopril on central blood pressure accounted probably 
for a significant part of the different effect on cardiovascular 
outcome observed in the ASCOT trial (Anglo-Scandinavian 
Cardiac Outcomes Trial), in which an advantage of the 
combination ACE inhibitor-calcium channel blocker was 
clearly observed. A more pronounced and favorable effect 
of calcium channel blockers, diuretics and ACE inhibitors 
compared with β-blockers on central aortic systolic blood 
pressure or central augmentation pressure was also observed 
by Morgan et al.17
However, it should be noted that, in the previously 
mentioned studies, the β-blocker investigated as the comparator 
drug was almost always atenolol. It is conceivable that newer 
β-blockers with additional vasodilating properties, such as 
nebivolol or carvedilol, which may possess favorable effects 
on carbohydrate and lipid metabolism, as well as on endothelial 
function and on oxidative stress, may have different and 
more favorable effects on arterial stiffness, as compared with 
atenolol.
Nebivolol, endothelial function  
and oxidative stress
Nebivolol is a third generation β-adrenergic receptor-blocking 
drug.18,19 It is a racemic mixture of D- and L-enantiomers, 
of which D-nebivolol is considered to be a highly selective 
β-adrenergic receptor antagonist. In addition, nebivolol has 
been demonstrated to possess vasodilator properties both 
in experimental animals and in humans. This effect may be 
attributable to the ability of nebivolol to increase nitric oxide 
(NO) bioavailability, as demonstrated in animals, human 
volunteers and hypertensive patients.18,20–22 Nebivolol may 
also possess antiproliferative properties that are potentially 
useful in terms of regression of vascular structural changes, 
as frequently observed in hypertensive patients.23 New 
important findings on the metabolic profile of nebivolol and 
on its protective effects on oxidative stress were recently 
made available. Fratta Pasini et al24 have demonstrated that 
nebivolol decreases oxidative stress in essential hypertension 
and increases NO by reducing its oxidative inactivation. In 
fact, in 20 hypertensive patients, both nebivolol and atenolol 
significantly reduced blood pressure values after 4 weeks 
of treatment.24 Plasma and low density lipoproteins (LDL) 
hydroperoxides, plasma 8-isoprostanes, plasma oxidized 
LDL and LDL lag phase (and index of susceptibility of LDL 
to oxidation) were significantly improved only in patients 
receiving nebivolol. Similarly, there was a reduction of 
reactive oxygen species (ROS) and of superoxide anion 
concentration in cultured endothelial cells exposed to 
oxidative stress after incubation with plasma of patients 
treated with nebivolol, while no effect was seen with plasma 
obtained from patients treated with atenolol. Furthermore, the 
reduction of NO production by endothelial cells induced by 
oxidative stress was significantly lower in patients receiving 
nebivolol compared with those given atenolol. These findings 
strongly support the hypothesis that nebivolol may increase 
NO by reducing its oxidative inactivation. In this regard, a 
relevant role might be played by an inhibition of superoxide 
formation by NADPH oxidase through a prevention of 
NADPH subunit assembly.25
Nebivolol might also improve endothelial function 
by increasing NO production through a stimulation of 
constitutive NO-synthase (eNOS), or by reducing oxidative 
inactivation of NO. Dessy et al26 suggested as a possible 
explanation for the stimulation of eNOS by nebivolol 
also the involvement of β-3 adrenoceptors. Alternatively, 
nebivolol might reduce asymmetric dimethylarginine 
(ADMA) circulating levels, being ADMA a potent inhibitor 
of eNOS.27
These properties of nebivolol seem to be linked to the 
chemical structure of the drug since they are present also in 
its 4-keto derivative,28 as demonstrated in a study performed 
in bovine aortic endothelial cells and in human umbilical 
vein endothelial cell culture. The observed antioxidant 
properties of nebivolol seem to be highly specific, since, in 
a clinical study, Taddei et al29 could not observe any effect 
on endothelial function (acetylcholine-induced vasodilatation 
in the forearm) and on oxidative stress using a different 
β-blocker, atenolol, given to 10 hypertensive patients. 
Therefore, available data suggest that nebivolol may exert 
relevant protective actions on endothelium, by increasing NO 
bioavailability. Antioxidant properties of nebivolol, and its 
neutral or even favorable effects on both carbohydrate and 
lipid metabolism,20,31 seem to be well documented.18
Nebivolol and large artery stiffness
An increased oxidative stress or a decreased NO production 
may be involved in the development of structural alterations 
in large arteries, including changes in the mechanical 
properties.1,32 Also in a recent evaluation of markers of 
vascular stiffness, performed in the Framingham population, 
a marker of endothelial function, namely PAI-1 production, 
was found to be related to central pulse pressure and to 
and forward pressure wave.33 Therefore, the NO-mediated 
effects of nebivolol might theoretically lead to a reversal Vascular Health and Risk Management 2009:5 357
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of endothelial dysfunction and to a decrease of large artery 
stiffness and of systemic vascular resistance.34
Mahmud and Feely35 compared the effects of the β-blockers 
atenolol and nebivolol on indices of arterial stiffness in 
40 subjects with untreated hypertension. Arterial stiffness was 
assessed in terms of carotid-femoral PWV (Complior®) and 
arterial wave reflection (augmentation index by applanation 
tonometry, Sphygmocor®). Both β-blockers produced an 
equal reduction in brachial blood pressure, but aortic pulse 
pressure was reduced to a greater extent by nebivolol (from 
51 ± 2 to 35 ± 2 mmHg, p  0.01) compared with atenolol 
(from 54 ± 3 to 43 ± 3 mmHg, p  0.05). PWV was decreased 
significantly by both therapies but only nebivolol significantly 
reduced augmentation index (Figure 3). In addition, whereas 
pulse pressure amplification decreased during treatment 
with atenolol, it increased during treatment with nebivolol 
(Figure 3). Atenolol reduced heart rate to a greater extent than 
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Figure 3 Changes in pulse wave velocity, augmentation index and pulse pressure amplification in 40 hypertensive patients treated with nebivolol or atenolol for 4 weeks.
*= p  0.05; **= p  0.01 vs Basal. Reproduced by permission from Macmillan Publishers Ltd: Mahmud A, Feely J. Beta-blockers reduce aortic stiffness in hypertension but 
nebivolol, not atenolol, reduces wave reflection. Am J Hypertens. 2008;21:663–667.34 Copyright © 2008.Vascular Health and Risk Management 2009:5 358
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8 ± 2 beats per minute reduction by nebivolol, p  0.05). It 
is possible, therefore, that nebivolol, in contrast to atenolol, 
may have an effect on small resistance arteries, increasing 
pulse pressure amplification and reducing wave reflection, 
possibly because of increased local levels of NO. The 
authors concluded that such ancillary properties may be 
relevant in terms of impact on hemodynamics, suggesting 
that β-blockers cannot be regarded as a homogeneous group 
in this regard.35
In a study by Dikram et al36 nebivolol and atenolol had 
similar effects on brachial blood pressure and aortic stiffness 
(Table 1). However, nebivolol reduced aortic pulse pressure 
more than atenolol (Table 1), and this effect may have been 
related to a less pronounced rise in augmentation index and 
to less bradycardia. When nebivolol was compared with 
the ACE inhibitor enalapril, in terms of effects on insulin 
sensitivity, hemodynamics and arterial stiffness, no difference 
between the two drugs was observed, thus suggesting that 
nebivolol shared with enalapril beneficial effects on arterial 
compliance and on glucose metabolism in hypertensive 
diabetic patients.37 The direct effects of β-blockade on 
PWV, which, as previously mentioned, is a robust measure 
of arterial distensibility, were investigated in an ovine, 
hind-limb animal model.38 The results demonstrated that 
nebivolol, but not atenolol, increases arterial distensibility, 
independently of any effect on blood pressure. This effect of 
nebivolol seemed to be mediated through the release of NO 
via a β-2 adrenoceptor-dependent mechanism.38
Finally, Arosio et al39 demonstrated that nebivolol and 
atenolol significantly reduced diastolic blood pressure and 
heart rate, favorably modulating response to handgrip. Nebiv-
olol, but not atenolol, improved small artery distensibility 
index and endothelial function, as evaluated by endothe-
lium-dependent cutaneous vasodilation after acetylcholine, 
although the distensibility index of small arteries evaluated 
by the authors (time to peak divided by total time of the 
pressure curve obtained from a digital artery) seems to have 
some limitations.40
In general, it is possible to conclude that the beneficial 
effects of nebivolol on arterial stiffness41–43 and endothelial 
dysfunction44 are consistently demonstrated, and differ from 
those observed with atenolol.
Conclusions
Several findings confirm that nebivolol, a highly selective 
β-1-blocker, endowed with additional vasodilating activity 
mediated by NO endothelial release, differs from other 
β-blocking agents, and that the combination of β-1 blockade 
and NO-mediated vasodilation leads to a broader favorable 
metabolic profile, and to beneficial effects on arterial 
stiffness;41,43 these properties may be clinically relevant in the 
treatment of hypertensive patients.45 In particular, antioxidant 
and endothelial-protective properties and neutral or favorable 
effects on both carbohydrate and lipid metabolisms seem 
to be well documented.18 These properties consistently 
differentiate nebivolol from non-vasodilating β-blockers, and 
Table 1 Hemodynamic and biochemical parameters following therapy with nebivolol or atenolol
Parameter Atenolol (A) Nebivolol (N) Placebo Overall significance Significance A versus N
Brachial SBP (mm Hg) 137 ± 3* 136 ± 3* 149 ± 3 0.003 0.4
Brachial DBP (mm Hg) 73 ± 2 75 ± 2 82 ± 2 0.001 0.5
Brachial PP (mm Hg) 64 ± 2* 61 ± 3* 67 ± 3 −0.2 –
MAP (mm Hg) 94 ± 3* 95 ± 2* 104 ± 2 0.001 0.8
Aortic SBP (mm Hg) 127 ± 3* 125 ± 3* 131 ± 2 0.03 0.4
Aortic DBP (mm Hg) 73 ± 2 75 ± 2 82 ± 2 0.001 0.3
Aortic PP (mm Hg) 54 ± 2* 50 ± 2 49 ± 2 0.001 0.02
PP amplification 1.20 ± 0.02 1.22 ± 0.02 1.39 ± 0.03 0.001 0.7
Heart rate (beats/min) 57 ± 1 61 ± 2 80 ± 3 0.001 0.009
Aix (%) 32 ± 2* 28 ± 2* 22 ± 2 0.001 0.04
Aortic PwV (m/s) 8.9 ± 0.3* 9.1 ± 0.3* 10.0 ± 0.04 0.001 0.2
Adapted with permission from Dhakam Z,   Yasmin, Mceniery CM, Burton T, Brown MJ, wilkinson iB.   A comparison of atenolol and nebivolol in isolated systolic hypertension. 
J Hypertens. 2008; 26:351-236.36 Copyright © 2008 Lippincott williams & wilkins.
Notes: *indicates a significant change compared with the placebo phase for individual treatments based on custom hypothesis testing. Significance was determined using 
repeated-measures ANOVA for the two active drugs compared with the placebo phase. Data represent means ± SeM, or medians (interquartile range).
Abbreviations: Aix, augmentation index; DBP, diastolic blood pressure; MAP, mean arterial pressure; PP, pulse pressure; PwV, pulse wave velocity; SBP, systolic blood pressure.Vascular Health and Risk Management 2009:5 359
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may account for the favorable effects on arterial distensibility. 
Because endothelial dysfunction and arterial stiffness play 
an important role in the early atherosclerotic process and are 
associated with poor outcomes and increased mortality, inde-
pendent of blood pressure, the ability of nebivolol to enhance 
release of endothelium-derived NO may have significant 
clinical implications for the use of this agent in the treatment 
of hypertension and cardiovascular diseases.
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